100 episodes

This is the podcast site for iForumRx.org - a community of ambulatory care pharmacy specialists and others interested in the evidence regarding drug therapy and patient management.

iForumRx.org University of Mississippi School of Pharmacy

    • Health & Fitness
    • 4.9 • 29 Ratings

This is the podcast site for iForumRx.org - a community of ambulatory care pharmacy specialists and others interested in the evidence regarding drug therapy and patient management.

    Can Losing Weight Using Semaglutide Prevent a Heart Attack, Ack, Ack, Ack, Ack?

    Can Losing Weight Using Semaglutide Prevent a Heart Attack, Ack, Ack, Ack, Ack?

    Weight extremes, a body-mass index (BMI) either very underweight or obese, are associated with increased all-cause mortality.  Mortality attributable to obesity is caused by many secondary conditions like metabolic disorders and cardiovascular (CV) disease. Enter the glucagon-like peptide-1 (GLP-1) receptor agonists—initially approved in the treatment of type 2 diabetes— which induce significant weight loss regardless of diabetes status.  But can a weight loss drug decrease CV mortality?
    Guest Authors:  Gregory Castelli, PharmD, BCPS, BC-ADM, CDCES and Drake Meaney, PharmD, BCPS
    Music by Good Talk

    • 21 min
    Prescription for Savings: The Clinical and Economic Impact of Pharmacist-Led Hypertension Management in the U.S.

    Prescription for Savings: The Clinical and Economic Impact of Pharmacist-Led Hypertension Management in the U.S.

    Pharmacists are the most accessible health professionals and can play a vital role in screening and managing hypertension.  But would an expanded scope of practice that enabled pharmacists to prescribe and manage antihypertensive therapies be cost-effective?
    Guest Authors: Stefania Cian, PharmD and Candice Garwood, PharmD, FCCP, BCPS, BCACP 
    Special Guest: Dave Dixon, PharmD, BCACP, CLS
    Music by Good Talk

    • 22 min
    Heartburn Headache: Cumulative PPI Use and Dementia Risk

    Heartburn Headache: Cumulative PPI Use and Dementia Risk

    Omeprazole ranks among the top 10 most prescribed medications in the United States, and many patients take proton pump inhibitors (PPIs) for years. Widespread PPI use persists despite data about potential serious adverse effects.  Some worry that PPI use increases the risk of dementia.  Are those worries supported by data?
    Guest Authors:  Molly M. Corder, PharmD, BCPS, BCACP and Ryan S. Ades, PharmD, BCPS
    Music by Good Talk

    • 22 min
    Does Size Matter? The Surprising Impact of Cuff Size on Blood Pressure Readings

    Does Size Matter? The Surprising Impact of Cuff Size on Blood Pressure Readings

    Most clinical settings now use oscillometric BP devices to measure patients’ BP, and over half of people with hypertension (HTN) use a home BP monitor.   Can we trust these BP readings if an inappropriate cuff size was used? How will this impact the way we assess BP control?
    Guest Authors:  Vincent Lam, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP, CDCES
    Music by Good Talk

    • 18 min
    Defining the Role of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction

    Defining the Role of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction

    Over 75% of heart failure with preserved ejection fraction (HFpEF) patients have a comorbid diagnosis of obesity. Obesity is an independent risk factor for the development of HFpEF and contributes to disease progression. Obese patients with HFpEF have greater symptom burden, reduced functional capacity, and impaired quality of life when compared to those without obesity.  We know that patients often struggle to adhere to lifestyle modifications long enough to see meaningful weight loss, but the benefits of GLP-1 agonists for patients with HFpEF who are obese are not yet clear.
    Guest Authors: Alicia M. Nordberg-Payne, PharmD; Rebecca Munger, PharmD, BCACP; Jason Zupec, PharmD, BCACP
    Music by Good Talk

    • 20 min
    Do Statins “REPRIEVE” People Living with HIV from CV Events?

    Do Statins “REPRIEVE” People Living with HIV from CV Events?

    As people living with HIV age, the risk of cardiovascular disease becomes the greatest threat to their health and quality of life. Not only does inflammation from HIV infection contribute to atherosclerotic cardiovascular disease (ASCVD), but dyslipidemia from the antivirals commonly used to treat HIV further enhances that risk. But does statin therapy reduce ASCVD risk in patients living with HIV?  That's the question that the REPRIEVE study attempted to answer.
    Guest Authors:  Laura Lerner, PharmD and Joseph Nardolillo, PharmD, BCACP
    Music by Guest Talk

    • 20 min

Customer Reviews

4.9 out of 5
29 Ratings

29 Ratings

DavRAla2 ,

Concise and interesting

Appreciate the fact that always start with case study and try to relate study to actual practice.

RxLaura ,

Great!

A very informative and concise podcast to help keep updated on ambulatory care areas

Top Podcasts In Health & Fitness

Huberman Lab
Scicomm Media
ZOE Science & Nutrition
ZOE
The School of Greatness
Lewis Howes
On Purpose with Jay Shetty
iHeartPodcasts
Pursuit of Wellness
Mari Llewellyn
Ten Percent Happier with Dan Harris
Ten Percent Happier

You Might Also Like

Diabetes Core Update
American Diabetes Association
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
Eric Christianson, PharmD; Pharmacology Expert and Clinical Pharmacist
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
JAMA Clinical Reviews
JAMA Network
Cardionerds: A Cardiology Podcast
CardioNerds
The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
Pharmacy Joe